The MI-2 (2-Chloro-N-[4-[5-(3,4-dichlorophenyl)-3-(2-methoxyethoxy)-1H-1,2,4-triazol-1-yl]phenylacetamide]) has been demonstrated as a MALT1 inhibitor which decreases MALT1-induced NF-κB activity in lymphoma (ABC-DLBCL) and cholangiocarcinoma cells [27,44]. This evidence concerns the gene NFKB1 and aneurysmal bone cyst.